Wrecklimid: How treating generic drugs as something special can wreck affordability
In late 2025, the Congressional Budget Office (CBO) issued an unusual request – a call for new research into Medicare Part D spending. The request stemmed from CBO’s own observations regarding Part D spending, which showed that federal spending on the Medicare Part D benefit, which covers prescrip
Comments (0)
No comments yet








